Lisata Therapeutics (LSTA) Free Cash Flow (2016 - 2025)
Lisata Therapeutics filings provide 13 years of Free Cash Flow readings, the most recent being -$3.2 million for Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow rose 28.25% year-over-year to -$3.2 million, compared with a TTM value of -$16.0 million through Dec 2025, up 17.46%, and an annual FY2025 reading of -$16.0 million, up 17.46% over the prior year.
- Free Cash Flow hit -$3.2 million in Q4 2025 for Lisata Therapeutics, up from -$3.3 million in the prior quarter.
- The five-year high for Free Cash Flow was -$2.5 million in Q3 2024, with the low at -$8.2 million in Q1 2023.
- Median Free Cash Flow over the past 3 years was -$4.1 million (2023), compared with a mean of -$4.6 million.
- The sharpest move saw Free Cash Flow increased 29.72% in 2024, then crashed 32.72% in 2025.
- Year by year, Free Cash Flow stood at -$4.1 million in 2023, then fell by 11.28% to -$4.5 million in 2024, then increased by 28.25% to -$3.2 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods came in at -$3.2 million, -$3.3 million, and -$4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.